Physician profile
Jonathan E Pleasant
NPI 1811998214
$906.23
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $304 · 2022: $336 · 2023: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $245.92 | 2021-2023 | Saxenda, Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $145.49 | 2021-2023 | Shingrix, Arexvy |
| Lundbeck LLC | $73.75 | 2022-2023 | Vyepti |
| Lilly USA, LLC | $39.77 | 2022-2023 | Mounjaro |
| Nevro Corp. | $34.90 | 2022 | |
| Daiichi Sankyo INC. | $33.89 | 2022-2023 | Injectafer |
| Seqirus USA INC | $33.79 | 2022 | |
| Pfizer INC. | $33.69 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $33.50 | 2021 | |
| Inspire Medical Systems, INC. | $28.55 | 2023 | Inspire |
| Astellas Pharma US INC | $26.80 | 2022-2023 | Myrbetriq |
| Ibsa Pharma INC. | $24.86 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $22.39 | 2021 | |
| Tris Pharma INC | $19.85 | 2023 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.41 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16.92 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $16.58 | 2022 | |
| Dynavax Technologies Corporation | $16.31 | 2023 | Heplisav-B |
| Medtronic, INC. | $14.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.07 | 2022 | |
| Genentech USA, INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pleasant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.